Ovarian Cancer Clinical Trial

Clinical Trial Finder Ovarian Cancer Trials

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

See Locations Near You

Summary

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.

PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

View Full Description

Full Description

OBJECTIVES:

Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
Characterize the dose and tolerability of octreotide in this patient population.

OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.

Patients who respond well to study may continue octreotide for palliative effects.

PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Inoperable bowel obstruction secondary to cancer OR
Metastatic or primary abdominal cancer
Patient presents with vomiting
Percutaneous gastrostomy tube allowed

PATIENT CHARACTERISTICS:

Age:

Over 18

Performance status:

ECOG 0-4

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

Other:

No documented hypersensitivity to octreotide
Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Prior chemotherapy allowed

Endocrine therapy:

Concurrent steroids allowed

Radiotherapy:

Prior radiotherapy allowed

Surgery:

Not specified

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Study ID:

NCT00004895

Recruitment Status:

Completed

Sponsor:

Northwestern University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago Illinois, 60611, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Study ID:

NCT00004895

Recruitment Status:

Completed

Sponsor:


Northwestern University

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Promising Immunotherapy Trials for Ovarian Cancer
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider